- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04153292
Het ENCIRCLE-proces (ENCIRCLE)
SAPIEN M3-systeem Transkatheter Mitralisklepvervanging via transseptale toegang
This study will establish the safety and effectiveness of the SAPIEN M3 System in subjects with symptomatic, at least 3+ mitral regurgitation (MR) for whom commercially available surgical or transcatheter treatment options are deemed unsuitable.
Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
This is a prospective single-arm, multicenter study.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
-
Camperdown, Australië, NSW2050
- Royal Prince Alfred Hospital
-
-
Queensland
-
Chermside, Queensland, Australië, 4032
- The Prince Charles Hospital
-
-
-
-
-
Toronto, Canada, M5B 1W8
- St. Michael's
-
Vancouver, Canada, V6E 1M7
- St. Pauls
-
-
Quebec
-
Québec, Quebec, Canada, G1V 0A6
- Laval University
-
-
-
-
-
Petah Tikva, Israël, 4941492
- Rabin Medical Center
-
-
-
-
-
Leiden, Nederland, 2333 ZA
- Leiden University Medical Center
-
Rotterdam, Nederland, 3015 CE
- Rotterdam Erasmus MC
-
-
-
-
-
London, Verenigd Koninkrijk, EC1A 7BE
- Saint Bartholomew's Medical Center
-
London, Verenigd Koninkrijk, SE1 7EH
- Saint Thomas Hospital
-
-
-
-
Alabama
-
Huntsville, Alabama, Verenigde Staten, 35801
- Heart Center Hospital
-
-
Arizona
-
Phoenix, Arizona, Verenigde Staten, 85006
- Banner University Medical Center
-
Phoenix, Arizona, Verenigde Staten, 85013
- Saint Josephs Hospital Medical Center Dignity Health
-
-
California
-
La Jolla, California, Verenigde Staten, 92037
- Scripps Health
-
Los Angeles, California, Verenigde Staten, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, Verenigde Staten, 90017
- Good Samaritan Hospital
-
Los Angeles, California, Verenigde Staten, 90071
- Kaiser Sunset LA
-
San Francisco, California, Verenigde Staten, 94109
- California Pacific Medical Center
-
-
Colorado
-
Loveland, Colorado, Verenigde Staten, 80538
- UC Health Northern Colorado (Medical Center of the Rockies)
-
-
Florida
-
Gainesville, Florida, Verenigde Staten, 32605
- Cardiac & Vascular Institute Foundation
-
Jacksonville, Florida, Verenigde Staten, 32204
- Ascension St. Vincent's Hospital
-
Naples, Florida, Verenigde Staten, 34102
- Naples Community Hospital
-
Sarasota, Florida, Verenigde Staten, 34239
- Sarasota Memorial Hospital
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30308
- Emory University
-
Atlanta, Georgia, Verenigde Staten, 30309
- Piedmont Healthcare
-
-
Illinois
-
Glenview, Illinois, Verenigde Staten, 60026
- Northshore University Health System
-
-
Kansas
-
Kansas City, Kansas, Verenigde Staten, 66160
- University of Kansas
-
Wichita, Kansas, Verenigde Staten, 67226
- Cardiovascular Research Institute of Kansas (CRIOK)
-
-
Louisiana
-
Baton Rouge, Louisiana, Verenigde Staten, 70808
- Our Lady of the Lake Regional Medical Center
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21218
- Medstar Union Memorial Hospital
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02114
- Massachusetts General Hospital
-
-
Michigan
-
Detroit, Michigan, Verenigde Staten, 48202
- Henry Ford
-
-
Minnesota
-
Rochester, Minnesota, Verenigde Staten, 55905
- Mayo Clinic
-
Saint Cloud, Minnesota, Verenigde Staten, 56303
- CentraCare
-
-
Missouri
-
Kansas City, Missouri, Verenigde Staten, 64111
- Saint Luke's Kansas City
-
-
New Hampshire
-
Lebanon, New Hampshire, Verenigde Staten, 03756
- Dartmouth-Hitchcock Medical Center
-
-
New Jersey
-
New Brunswick, New Jersey, Verenigde Staten, 08901
- Robert Wood Johnson University Hospital
-
-
New York
-
Buffalo, New York, Verenigde Staten, 14203
- University of Buffalo
-
New York, New York, Verenigde Staten, 10007
- Weill Cornell Medicine
-
-
North Carolina
-
Charlotte, North Carolina, Verenigde Staten, 28204
- Novant Health and Vascular Institute
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45219
- The Christ Hospital
-
Cleveland, Ohio, Verenigde Staten, 44122
- Cleveland Clinic Foundation
-
Columbus, Ohio, Verenigde Staten, 43123
- Mount Carmel East Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Verenigde Staten, 73120
- Oklahoma Heart Hospital
-
Tulsa, Oklahoma, Verenigde Staten, 74104
- Oklahoma Heart Institute
-
-
Pennsylvania
-
Mechanicsburg, Pennsylvania, Verenigde Staten, 17050
- UPMC Heart and Vascular Institute
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37205
- Saint Thomas Health
-
-
Texas
-
Austin, Texas, Verenigde Staten, 78705
- Austin Heart
-
Houston, Texas, Verenigde Staten, 77030
- UT Memorial Hermann
-
Houston, Texas, Verenigde Staten, 77004
- HCA Houston Healthcare Medical (SCRI)
-
-
Utah
-
Murray, Utah, Verenigde Staten, 84107
- Intermountain Medical Center
-
-
Virginia
-
Norfolk, Virginia, Verenigde Staten, 23507
- Sentara Norfolk
-
Roanoke, Virginia, Verenigde Staten, 24014
- Carilion Roanoke Memorial Hospital
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98195
- University of Washington Seattle
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- 18 years of age or older
- MR ≥ 3+
- NYHA functional class ≥ II
- Per the Heart Team, commercially available surgical or transcatheter treatment options are deemed unsuitable due to clinical, anatomic or technical considerations.
- Subject's heart failure management has been optimized based on subject characteristics and applicable guidelines, and stable for at least 30 days prior to enrollment.
- The subject or subject's legal representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent.
Exclusion Criteria:
- Mitral/cardiac anatomy that would preclude appropriate delivery and deployment of the SAPIEN M3 dock or valve
- Inappropriate anatomy for femoral introduction and delivery of the SAPIEN M3 dock and valve
- Presence of any device that will contact or interfere with the SAPIEN M3 System during delivery or after implantation
- Left ventricular ejection fraction <25%
- Severe right ventricular dysfunction
- Need for aortic, tricuspid or pulmonic valve intervention within the next 12 months
- History of heart transplant
- Cardiac imaging evidence of intracardiac mass, thrombus or vegetation
- Active bacterial endocarditis within 180 days of the procedure
- Hemodynamic instability requiring inotropic or mechanical support within 30 days of the procedure
- Myocardial infarction within 30 days of the procedure
- Clinically significant untreated coronary artery disease requiring revascularization
- Any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery within 30 days of the procedure
- Stroke or transient ischemic attack within 90 days of the procedure
- Irreversible, severe pulmonary hypertension
- Chronic obstructive pulmonary disease requiring home oxygen therapy or chronic outpatient oral steroid use
- Renal insufficiency or receiving renal replacement therapy
- Liver disease
- Planned surgery within the next 12 months
- Inability to tolerate or a medical condition precluding treatment with antithrombotic therapy, including heparin administration during the procedure
- Active infection requiring current antibiotic therapy
- Active SARS-CoV-2 infection (Coronavirus-19 [COVID-19]) or previously diagnosed with COVID-19 with sequelae that could confound endpoint assessments
- Leukopenia, anemia, thrombocytopenia, history of bleeding diathesis or coagulopathy or hypercoagulable states
- Refusal of blood products
- Female who is pregnant or lactating
- Estimated life expectancy <12 months due to non-cardiac conditions
- Participating in another investigational drug or device study that has not reached its primary endpoint
- Subject considered to be part of a vulnerable population
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: TMVR - Main Cohort
Subjects for whom commercially available surgical or transcatheter treatment options are deemed unsuitable will have transcatheter mitral valve replacement (TMVR). |
During the procedure a SAPIEN M3 dock and a SAPIEN M3 valve will be implanted via transseptal approach. |
|
Experimenteel: TMVR - Failed TEER Registry
Subjects who have had an attempted but failed transcatheter edge-to-edge repair (TEER) procedure will have TMVR. |
During the procedure a SAPIEN M3 dock and a SAPIEN M3 valve will be implanted via transseptal approach. |
|
Experimenteel: TMVR - MAC Registry
Subjects with mitral annular calcification (MAC) will have TMVR. |
During the procedure a SAPIEN M3 dock and a SAPIEN M3 valve will be implanted via transseptal approach. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Non-hierarchical composite of death and heart failure rehospitalization
Tijdsspanne: 1 year
|
Number of subjects with death and/or heart failure rehospitalization |
1 year
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Improvement in NYHA functional class compared to baseline
Tijdsspanne: 1 year
|
New York Heart Association (NYHA) functional classification of heart failure is based on how much a patient is limited during physical activity. The rating ranges from I-IV. I = no limitations of physical activity; II = slight limitations of physical activity, ordinary physical activity results in fatigue, palpitation, shortness of breath; III = marked limitations of physical activity, less than ordinary activity causes fatigue, palpitation, or shortness of breath; IV = unable to carry on any physical activity without discomfort, symptoms of heart failure at rest. |
1 year
|
|
Improvement in KCCQ Overall Score compared to baseline
Tijdsspanne: 1 year
|
The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. An overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. |
1 year
|
|
Improvement in MR compared to baseline
Tijdsspanne: 1 year
|
Number of subjects with improved MR compared to baseline |
1 year
|
|
Decrease in LVEDVi compared to baseline
Tijdsspanne: 1 year
|
Number of subjects with decreased left ventricular end-diastolic volume index (LVEDVi) compared to baseline |
1 year
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: John Webb, MD, St. Paul's Hospital
- Hoofdonderzoeker: Mayra Guerrero, MD, Mayo Clinic
- Hoofdonderzoeker: David Daniels, MD, California Pacific Medical Center
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 2018-19
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .